United Therapeutics Corporation
UTHR
$301.00
-$1.41-0.47%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 798.60M | 794.40M | 735.90M | 748.90M | 714.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 798.60M | 794.40M | 735.90M | 748.90M | 714.90M |
| Cost of Revenue | 87.60M | 92.50M | 75.90M | 83.10M | 77.80M |
| Gross Profit | 711.00M | 701.90M | 660.00M | 665.80M | 637.10M |
| SG&A Expenses | 212.50M | 170.10M | 164.30M | 154.10M | 177.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 434.10M | 411.60M | 374.00M | 340.70M | 395.00M |
| Operating Income | 364.50M | 382.80M | 361.90M | 408.20M | 319.90M |
| Income Before Tax | 408.40M | 423.50M | 396.50M | 388.60M | 355.30M |
| Income Tax Expenses | 98.90M | 101.30M | 95.20M | 79.50M | 77.20M |
| Earnings from Continuing Operations | 309.50M | 322.20M | 301.30M | 309.10M | 278.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 309.50M | 322.20M | 301.30M | 309.10M | 278.10M |
| EBIT | 364.50M | 382.80M | 361.90M | 408.20M | 319.90M |
| EBITDA | 385.60M | 402.60M | 381.60M | 427.30M | 338.60M |
| EPS Basic | 6.86 | 7.18 | 6.74 | 6.93 | 6.26 |
| Normalized Basic EPS | 5.72 | 5.97 | 5.63 | 6.31 | 5.00 |
| EPS Diluted | 6.41 | 6.63 | 6.18 | 6.39 | 5.85 |
| Normalized Diluted EPS | 5.34 | 5.51 | 5.17 | 5.82 | 4.67 |
| Average Basic Shares Outstanding | 45.10M | 44.90M | 44.70M | 44.60M | 44.40M |
| Average Diluted Shares Outstanding | 48.30M | 48.60M | 48.70M | 48.40M | 47.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |